Drug overpricing: Govt plans amnesty scheme to recover dues from pharma companies

In a bid to tackle overpricing in the pharmaceutical sector, the government is planning an amnesty scheme to recover dues from pharmaceutical companies, CNBC Aawaz reported.

The National Pharmaceutical Pricing Authority (NPPA), responsible for overseeing drug pricing, has identified a substantial 2,200 cases of overpricing within the pharmaceutical industry.

Among the companies under scrutiny for overpricing practices are well-known names such as Cipla, Sun Pharma, and Lupin. These cases collectively involve dues amounting to approximately Rs. 13,000 crore.

The amnesty scheme proposes relief for pharmaceutical companies, offering waivers on interest and penalties associated with the alleged overpricing issues.

Pharma makers get a year for GMP implementation, Mandaviya warns action on defaults

The primary objective of the amnesty scheme is to recover outstanding dues from these companies. It is estimated that the government aims to retrieve around Rs. 5,000 to 6,000 crore through this initiative.

How are drug prices regulated?

Periodically, the Health Ministry collaborates with experts to create the National List of Essential Medicines (NLEM). This list includes medications vital for treating prevalent conditions and falls under price control through the Drug Price Control Order (DPCO).

The NPPA, a part of the Indian Government, was established to regulate drug prices. It enforces pricing and availability of medicines as per the Drugs (Prices Control) Order, 1995. NPPA also recovers overcharged amounts from consumers and monitors prices of unregulated drugs to ensure affordability.

Related Posts

  • Pharma
  • July 22, 2025
  • 152 views
DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

  • Pharma
  • July 16, 2025
  • 577 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug